Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

On June 28, 2012, the most significant scientific breakthrough of the first quarter of the 21st century was announced to the ...

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $67.21, marking a +1.04% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.58% for the day ...

The influenza A virus (IAV) has been the cause of six major flu pandemics, responsible for 50 to 100 million deaths globally.

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...

VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, Inc. for the use of select CRISPR-based ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout ...